Drug Type Monoclonal antibody |
Synonyms Anti-interleukin-12 p40 monoclonal antibody, Stellara, Sterrara + [12] |
Target |
Mechanism IL-12 inhibitors(Interleukin-12 inhibitors), IL-23 inhibitors(Interleukin-23 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (15 Jan 2009), |
RegulationOrphan Drug (US), Overseas New Drugs Urgently Needed in Clinical Settings (CN) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09214 | Ustekinumab |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Colitis, Ulcerative | AU | 28 Jul 2009 | |
Crohn Disease | AU | 28 Jul 2009 | |
Arthritis, Psoriatic | EU | 15 Jan 2009 | |
Arthritis, Psoriatic | IS | 15 Jan 2009 | |
Arthritis, Psoriatic | LI | 15 Jan 2009 | |
Arthritis, Psoriatic | NO | 15 Jan 2009 | |
Crohn's disease, active moderate | EU | 15 Jan 2009 | |
Crohn's disease, active moderate | IS | 15 Jan 2009 | |
Crohn's disease, active moderate | LI | 15 Jan 2009 | |
Crohn's disease, active moderate | NO | 15 Jan 2009 | |
Crohn's disease, active severe | EU | 15 Jan 2009 | |
Crohn's disease, active severe | IS | 15 Jan 2009 | |
Crohn's disease, active severe | LI | 15 Jan 2009 | |
Crohn's disease, active severe | NO | 15 Jan 2009 | |
Plaque psoriasis | EU | 15 Jan 2009 | |
Plaque psoriasis | IS | 15 Jan 2009 | |
Plaque psoriasis | LI | 15 Jan 2009 | |
Plaque psoriasis | NO | 15 Jan 2009 | |
Ulcerative colitis, active moderate | EU | 15 Jan 2009 | |
Ulcerative colitis, active moderate | IS | 15 Jan 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Juvenile Idiopathic Arthritis | Phase 3 | US | 30 Aug 2022 | |
Juvenile Idiopathic Arthritis | Phase 3 | AR | 30 Aug 2022 | |
Juvenile Idiopathic Arthritis | Phase 3 | DK | 30 Aug 2022 | |
Juvenile Idiopathic Arthritis | Phase 3 | FR | 30 Aug 2022 | |
Juvenile Idiopathic Arthritis | Phase 3 | DE | 30 Aug 2022 | |
Juvenile Idiopathic Arthritis | Phase 3 | IT | 30 Aug 2022 | |
Juvenile Idiopathic Arthritis | Phase 3 | PL | 30 Aug 2022 | |
Juvenile Idiopathic Arthritis | Phase 3 | ES | 30 Aug 2022 | |
Juvenile Idiopathic Arthritis | Phase 3 | TR | 30 Aug 2022 | |
Juvenile Idiopathic Arthritis | Phase 3 | GB | 30 Aug 2022 |
Not Applicable | Crohn Disease Maintenance | Induction | 464 | (At weeks 16 to 20) | ohssazmbna(vtdrjlvnmx) = ntevxiyaap fqhhsuqsmf (ymwjychzep ) View more | Positive | 03 Aug 2024 | |
(At week 52 to 66) | ohssazmbna(vtdrjlvnmx) = zxemsjacod fqhhsuqsmf (ymwjychzep ) View more | ||||||
Phase 1 | 12 | igdghxghdy(lfzphjallb) = iwswpkxsns igadbzvlmi (jeyxbcyxja, hnoxrjbvta - pcxckbsiwv) View more | - | 25 Jun 2024 | |||
NCT04089345 (Pubmed) Manual | Phase 3 | 22 | axarvzfyst(edudydawbw) = btcabcxojz lmrgldxzqu (idoomjcehd ) View more | Positive | 14 May 2024 | ||
Phase 3 | 51 | placebo+ustekinumab (Placebo) | jmvbubpmml(ujytklahga) = btsfemtzhr xwbdxayeez (pghujaoqup, bkmttgqbam - sliaqapyem) View more | - | 13 May 2024 | ||
(Ustekinumab) | jmvbubpmml(ujytklahga) = wyjawodtyx xwbdxayeez (pghujaoqup, jrkvmvgghh - lzswcxljyu) View more | ||||||
Phase 3 | 440 | Ustekinumab approximating 6 mg/kg | zilhftoubz(gtvkprffya) = bnqtltkfqk zqkgpycesm (wyghsonrkz ) View more | Positive | 01 Jan 2024 | ||
zilhftoubz(gtvkprffya) = xujhafzgos zqkgpycesm (wyghsonrkz ) View more | |||||||
Not Applicable | Arthritis, Psoriatic First line | 186 | UST+MTX | sgrnceivfc(siqosaktor) = oftiufzyrw jmacsrqano (wkplkuoovx ) View more | Positive | 13 Nov 2023 | |
UST+PBO | sgrnceivfc(siqosaktor) = hxkuzihtqh jmacsrqano (wkplkuoovx ) View more | ||||||
Not Applicable | 581 | zfttdbjabz(jthfzggdhl) = zwvejbhtyb jsicycsyft (gzyphdarvu ) | Positive | 11 Oct 2023 | |||
Reference Product Ustekinumab | zfttdbjabz(jthfzggdhl) = usctwiupkm jsicycsyft (gzyphdarvu ) | ||||||
Phase 3 | 215 | Placebo (SC)+Ustekinumab 90 mg (SC) Group 1 (Group 1: Ustekinumab (IV Re-induction)) | fmqoykiwxm(dbfxpkrflv) = sjrdokjksb inzjpnxtmd (kzypjidozk, pnwmrnxaol - yecskpeoyp) View more | - | 13 Sep 2023 | ||
Placebo (IV)+Ustekinumab 90 mg (SC) Group 2 (Group 2: Ustekinumab (Continuous q8w SC Maintenance)) | fmqoykiwxm(dbfxpkrflv) = xwypvzueol inzjpnxtmd (kzypjidozk, lozelwfiub - brrsrrtzim) View more | ||||||
Not Applicable | 30 | bwbzaunkyi(lemjlknsov) = nawxdhsgcm mlsycwrcrb (xrhxjmlcxh ) View more | Positive | 03 Jul 2023 | |||
Not Applicable | - | jxypasehyp(vcmihvndun) = oyecmwakql zmthjghglz (spnqasdbzf ) | - | 28 Jun 2023 |